Katsura Yoshiteru, Takeda Yutaka, Ohmura Yoshiaki, Sakamoto Takuya, Kawai Kenji, Inatome Junichi, Murakami Kohei, Naito Atsushi, Kagawa Yoshinori, Masuzawa Toru, Takeno Atsushi, Hata Taishi, Egawa Chiyomi, Murata Kohei
Dept. of Surgery, Kansai Rosai Hospital.
Gan To Kagaku Ryoho. 2019 Dec;46(13):2101-2103.
The efficacy of lenvatinib was evaluated in 7 patients with advanced hepatocellular carcinoma(HCC), between March 2018 and February 2019. Their mean age was 74.3 years, and 6 of them were men. All patients had an Eastern Cooperative Oncology Group(ECOG)performance status(PS)of 0. The median number of treatment days was 185. The relative dose intensity was 87.5%. The major Grade was 3, and the overall toxicity events were AST elevation(14.3%)and hypertension (14.3%). The 6-month progression-free and overall survival rates were 71.4% and 100%, respectively. The overall response rate was 57.1%, and the disease control rate was 71.4%. Lenvatinib can be used as a standard treatment for patients with advanced HCC.
